Tech Company Financing Transactions
Syndax Pharmaceuticals Funding Round
On 9/22/2014, Syndax Pharmaceuticals raised $4.9 million in investment from private investors.
Transaction Overview
Company Name
Announced On
9/22/2014
Transaction Type
Debt
Amount
$4,947,480
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Totten Pond Road 110
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a Waltham, MA-based, oncology-focused biotechnology company that is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Briggs Morrison
Chief Financial Officer
Allan Shaw
Chief Technical Officer
Peter Ordentlich
President
Michael Metzger
VP - Operations
Jeannette Hasapidis
Browse more venture capital transactions:
Prev: 9/22/2014: Mixmax venture capital transaction
Next: 9/22/2014: First Warning Systems venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs